This HTML5 document contains 63 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00657/identifier/chemspider/
foafhttp://xmlns.com/foaf/0.1/
n27http://linked.opendata.cz/resource/mesh/concept/
n5http://linked.opendata.cz/resource/drugbank/company/
n25http://linked.opendata.cz/resource/drugbank/dosage/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00657/identifier/wikipedia/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00657/identifier/pharmgkb/
n18http://bio2rdf.org/drugbank:
n19http://linked.opendata.cz/resource/drugbank/drug/DB00657/identifier/kegg-compound/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00657/identifier/bindingdb/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00657/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n22http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00657/identifier/pubchem-substance/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n20http://linked.opendata.cz/resource/drugbank/drug/DB00657/identifier/drugbank/
owlhttp://www.w3.org/2002/07/owl#
n26http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00657/identifier/iuphar/
n7http://www.drugs.com/cdi/
n24http://www.rxlist.com/cgi/generic2/
n4http://linked.opendata.cz/resource/drugbank/property/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00657/identifier/guide-to-pharmacology/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/resource/drugbank/drug/DB00657/identifier/national-drug-code-directory/
n29http://linked.opendata.cz/resource/atc/
n28http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00657
rdf:type
n3:Drug
n3:description
A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool. [PubChem]
n3:dosage
n25:271B637F-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:indication
For the treatment of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension
n3:manufacturer
n5:271B637E-363D-11E5-9242-09173F13E4C5
owl:sameAs
n18:DB00657 n22:DB00657
dcterms:title
Mecamylamine
adms:identifier
n10:50061565 n11:3892 n12:4032 n13:46508607 n14:17205-0626-1 n15:PA450334 n16:3990 n19:C07511 n20:DB00657 n21:3990 n23:Mecamylamine
n3:mechanismOfAction
Mecamylamine is a ganglionic blocker which prevents stimulation of postsynaptic receptors by acetylcholine released from presynaptic nerve endings. The hypotensive effect of Mecamylamine is attributed to reduction in sympathetic tone, vasodilation, and reduced cardiac output, and is primarily postural.
n3:packager
n5:271B637D-363D-11E5-9242-09173F13E4C5 n5:271B637C-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Mecamylamine is excreted slowly in the urine in the unchanged form. The rate of its renal elimination is influenced markedly by urinary pH. Alkalinization of the urine reduces, and acidification promotes, renal excretion of mecamylamine. Mecamylamine crosses the blood-brain and placental barriers.
n3:synonym
Versamine
n3:proteinBinding
40%
n3:salt
n3:synthesisReference
U.S. Patent 2,831,027.
n26:hasConcept
n27:M0013160
foaf:page
n7:mecamylamine.html n24:mecamylamine.htm
n3:IUPAC-Name
n4:271B6384-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B638A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B6389-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B6386-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B6387-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B6388-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B6382-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B6380-363D-11E5-9242-09173F13E4C5 n4:271B639B-363D-11E5-9242-09173F13E4C5 n4:271B6383-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B6381-363D-11E5-9242-09173F13E4C5
n28:hasATCCode
n29:C02BB01
n3:H-Bond-Acceptor-Count
n4:271B6390-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B6391-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B638B-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B638C-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B638E-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B638D-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B638F-363D-11E5-9242-09173F13E4C5
n3:absorption
Mecamylamine is almost completely absorbed from the gastrointestinal tract
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
60-40-2
n3:Bioavailability
n4:271B6395-363D-11E5-9242-09173F13E4C5
n3:Boiling-Point
n4:271B639A-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B6397-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B6398-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B6399-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B6394-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B6393-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B6396-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B6385-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B6392-363D-11E5-9242-09173F13E4C5